Sugi Predict

Sugi Predict / Compounds / SCHEMBL10151406

SCHEMBL10151406

SCHEMBL10151406

Cc1cc2ccncc2n1C

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.47
▸ TOP2A P11388 1/20 0.44
▸ CYP19A1 P11511 2/20 0.43
▸ ATM Q13315 1/20 0.41
▸ ADORA3 P0DMS8 1/20 0.41
▸ ADORA2A P29274 1/20 0.41
▸ SLC6A2 P23975 1/20 0.40
▸ KCNH2 Q12809 2/20 0.39
▸ HASPIN Q8TF76 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ RAPGEF4 Q8WZA2 1/20 0.39
▸ PDE10A Q9Y233 1/20 0.38
▸ AOC3 Q16853 1/20 0.37
▸ NAMPT P43490 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formamide SCHEMBL28426147 0.90 MAPT (0.41) MAPTTOP2ACYP19A1ATMADORA3
SCHEMBL10151401 0.84 ATM (0.45) MAPTTOP2ACYP19A1ATMADORA3
SCHEMBL19233631 0.78 MAPT (0.40) MAPTTOP2ACYP19A1SLC6A2KCNH2
SCHEMBL22502909 0.78 MAPT (0.46) MAPTTOP2ACYP19A1KCNH2HASPIN
SCHEMBL19233685 0.78 MAPT (0.46) MAPTTOP2ACYP19A1KCNH2HASPIN
SCHEMBL29856207 0.76 MAPT (0.44) MAPTTOP2ACYP19A1ATMKCNH2
SCHEMBL22792465 0.76 MAPT (0.44) MAPTTOP2ACYP19A1ATMADORA3
SCHEMBL29856743 0.76 MAPT (0.44) MAPTTOP2ACYP19A1ATMADORA3
SCHEMBL22793033 0.76 ALOX5AP (0.38) MAPTTOP2ACYP19A1SLC6A2KCNH2
SCHEMBL14327804 0.76 MAPT (0.44) MAPTTOP2ACYP19A1ATMADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115867549-A 1H-pyrrolo [3,2-c ] pyridine and 1H-pyrrolo [2,3-c ] pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis 百时美施贵宝公司 2023-03-28 — — CN claimed
US-12522598-B2 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as HDAC6 inhibitors ORYZON GENOMICS SA (ES) 2026-01-13 — — US disclosed
US-20230172053-A1 COMPOSITION, LIGHT-EMITTING DEVICE, ELECTRONIC APPARATUS, CONSUMER PRODUCT, AND ORGANOMETALLIC COMPOUND SAMSUNG DISPLAY CO., LTD. (KR) 2023-06-01 — — US disclosed
CN-115867549-A 1H-pyrrolo [3,2-c ] pyridine and 1H-pyrrolo [2,3-c ] pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis 百时美施贵宝公司 2023-03-28 — — CN disclosed
US-20220298156-A1 3-(2-(HETEROARYL)-PYRIDIN-4-YL)-5-(TRIFLUOROMETHYL)-1,2,4-OXADIAZOLE DERIVATIVES AS HDAC6 INHIBITORS ORYZON GENOMICS SA (ES) 2022-09-22 — — US disclosed
WO-2022169974-A1 INHIBITORS OF URAT1 AND PHARMACEUTICAL USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2022-08-11 — — WO disclosed
WO-2021113690-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 — — WO disclosed
WO-2021113698-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 — — WO disclosed
US-10707427-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2020-07-07 — — US disclosed
WO-2019243822-A1 1,2,4-TRIAZOLE DERIVATIVES AS TANKYRASE INHIBITORS OSLO UNIVERSITETSSYKEHUS HF (NO) 2019-12-26 — — WO disclosed
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE DANIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-12-11 — — US disclosed
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE DANIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-12-11 — — US disclosed
US-7425642-B2 Heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) 2008-09-16 — — US disclosed
US-7425642-B2 Heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) 2008-09-16 — — US disclosed
EP-1337251-B1 MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB PHARMA CO (US) 2008-08-20 — — EP disclosed
US-20080167306-A1 Novel Heteroaryl Derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-07-10 — — US disclosed
US-20080167306-A1 Novel Heteroaryl Derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-07-10 — — US disclosed
US-7332497-B2 As inhibitors of protein kinases ABBOTT GMBH & CO KG (DE) 2008-02-19 — — US disclosed
US-7332497-B2 As inhibitors of protein kinases ABBOTT GMBH & CO KG (DE) 2008-02-19 — — US disclosed
EP-1837329-A1 NOVEL HETEROARYL DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2007-09-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167306-A1 Novel Heteroaryl Derivative GPR119, SLC2A4, SLC5A2 MAPT 4727/4885TOP2A 4451/4885CYP19A1 246/4885
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE NR0B1, UGT1A10, NR0B2 MAPT 3977/4885TOP2A 2223/4885CYP19A1 56/4885
US-10707427-B2 Organic electroluminescent materials and devices OCIAD2, OCIAD1, JUND MAPT 440/4885TOP2A 3734/4885CYP19A1 2188/4885
US-20220298156-A1 3-(2-(HETEROARYL)-PYRIDIN-4-YL)-5-(TRIFLUOROMETHYL)-1,2,4-OXADIAZOLE DERIVATIVES AS HDAC6 INHIBITORS HDAC6, HDAC1, HDAC3 MAPT 616/4885TOP2A 113/4885CYP19A1 4338/4885
US-20230172053-A1 COMPOSITION, LIGHT-EMITTING DEVICE, ELECTRONIC APPARATUS, CONSUMER PRODUCT, AND ORGANOMETALLIC COMPOUND CYP1A1, CYP1B1, GPX1 MAPT 2762/4885TOP2A 4752/4885CYP19A1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.